首页 > 最新文献

Breast Cancer : Basic and Clinical Research最新文献

英文 中文
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study. 通过循环肿瘤 DNA 分析检测 HER2 阳性早期乳腺癌微小残留病灶并配合新辅助化疗的多中心前瞻性研究:HARMONY 研究。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-27 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241288671
Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki, Cyrielle Marie N Atutubo, Rubi K Li, Minda Z Perez, Agnes E Gorospe, Manuelito A Madrid, Mel Valerie C Ordinario, Marcelo Severino B Imasa, Kazuki Sudo, Tatsunori Shimoi, Akihiko Suto, Shinji Kohsaka, Ryunosuke Machida, Ryo Sadachi, Masayuki Yoshida, Yasushi Yatabe, Tomomi Hata, Kenichi Nakamura, Kan Yonemori, Sho Shiino

Background: Biomarkers to predict the recurrence risk are required to optimize perioperative treatment. Adjuvant chemotherapy for patients with human epidermal growth factor 2-positive (HER2-positive) early breast cancer is decided by pathological responses of neoadjuvant chemotherapy (NAC). However, whether pathological responses are appropriate biomarkers is unclear. Currently, there are several studies using minimal residual disease (MRD) as a predictor of prognosis in solid tumors. However, there is no standard method for detecting MRD.

Objectives: This study aimed at prospectively evaluating the relationship between MRD detection and recurrence in Asian patients with HER2-positive early breast cancer.

Design: Prospective, observational, single-group, and exploratory. This study will include 60 patients from 2 institutions in Japan and the Philippines. The invasive disease-free survival (IDFS) rates of the MRD-positive and MRD-negative groups are compared in patients with HER2-positive early breast cancer who undergo surgery after receiving NAC.

Methods and analysis: Circulating tumor DNA (ctDNA) levels of patients will be evaluated 6 times: before NAC, after NAC, after surgery, and annually after surgery for 3 years. We will analyze the genetic profile of blood and tissue samples using the Todai OncoPanel (TOP) and the methylation level of DNA. The primary endpoint is IDFS. Secondary endpoints include overall survival (OS) and disease-free survival (DFS). Patient enrollment began in June 2022, and new participants are still being recruited.

Ethics: This study has been approved by the National Cancer Center Hospital Certified Review Board in March 2022 and has been approved by the Research Ethics Board of the participating center.

Discussion: Our findings will contribute to determining whether MRD detection using TOP is useful for predicting the recurrence of HER2-positive early breast cancer. If this is proven, MRD detected by TOP could be used in the future as a biomarker to assist in the de-/escalation of treatment strategies in the next interventional trial, thereby avoiding overtreatment in patients at low risk, and in the addition of intensive treatment modalities for those in patients at high risk.

背景:预测复发风险的生物标志物是优化围手术期治疗所必需的。人类表皮生长因子 2 阳性(HER2 阳性)早期乳腺癌患者的辅助化疗是根据新辅助化疗(NAC)的病理反应决定的。然而,病理反应是否是适当的生物标志物尚不清楚。目前,有几项研究将最小残留病灶(MRD)作为实体瘤预后的预测指标。然而,目前还没有检测MRD的标准方法:本研究旨在前瞻性评估亚洲 HER2 阳性早期乳腺癌患者 MRD 检测与复发之间的关系:设计:前瞻性、观察性、单组和探索性。本研究将包括来自日本和菲律宾两家机构的 60 名患者。比较接受 NAC 后接受手术的 HER2 阳性早期乳腺癌患者中 MRD 阳性组和 MRD 阴性组的侵袭性无病生存率(IDFS):将对患者的循环肿瘤DNA(ctDNA)水平进行6次评估:NAC前、NAC后、手术后以及手术后3年内的每年评估。我们将使用 Todai OncoPanel(TOP)分析血液和组织样本的基因图谱以及 DNA 的甲基化水平。主要终点是 IDFS。次要终点包括总生存期(OS)和无病生存期(DFS)。患者招募始于 2022 年 6 月,目前仍在招募新的参与者:本研究已于2022年3月获得国家癌症中心医院认证审查委员会的批准,并已获得参与中心研究伦理委员会的批准:我们的研究结果将有助于确定使用TOP检测MRD是否有助于预测HER2阳性早期乳腺癌的复发。如果这一点得到证实,那么在下一次干预试验中,TOP检测到的MRD可作为一种生物标志物,协助治疗策略的去级/升级,从而避免低危患者的过度治疗,并为高危患者增加强化治疗模式。
{"title":"Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.","authors":"Momoko Tokura, Mark Malalay Ando, Yuki Kojima, Rui Kitadai, Shu Yazaki, Cyrielle Marie N Atutubo, Rubi K Li, Minda Z Perez, Agnes E Gorospe, Manuelito A Madrid, Mel Valerie C Ordinario, Marcelo Severino B Imasa, Kazuki Sudo, Tatsunori Shimoi, Akihiko Suto, Shinji Kohsaka, Ryunosuke Machida, Ryo Sadachi, Masayuki Yoshida, Yasushi Yatabe, Tomomi Hata, Kenichi Nakamura, Kan Yonemori, Sho Shiino","doi":"10.1177/11782234241288671","DOIUrl":"10.1177/11782234241288671","url":null,"abstract":"<p><strong>Background: </strong>Biomarkers to predict the recurrence risk are required to optimize perioperative treatment. Adjuvant chemotherapy for patients with human epidermal growth factor 2-positive (HER2-positive) early breast cancer is decided by pathological responses of neoadjuvant chemotherapy (NAC). However, whether pathological responses are appropriate biomarkers is unclear. Currently, there are several studies using minimal residual disease (MRD) as a predictor of prognosis in solid tumors. However, there is no standard method for detecting MRD.</p><p><strong>Objectives: </strong>This study aimed at prospectively evaluating the relationship between MRD detection and recurrence in Asian patients with HER2-positive early breast cancer.</p><p><strong>Design: </strong>Prospective, observational, single-group, and exploratory. This study will include 60 patients from 2 institutions in Japan and the Philippines. The invasive disease-free survival (IDFS) rates of the MRD-positive and MRD-negative groups are compared in patients with HER2-positive early breast cancer who undergo surgery after receiving NAC.</p><p><strong>Methods and analysis: </strong>Circulating tumor DNA (ctDNA) levels of patients will be evaluated 6 times: before NAC, after NAC, after surgery, and annually after surgery for 3 years. We will analyze the genetic profile of blood and tissue samples using the Todai OncoPanel (TOP) and the methylation level of DNA. The primary endpoint is IDFS. Secondary endpoints include overall survival (OS) and disease-free survival (DFS). Patient enrollment began in June 2022, and new participants are still being recruited.</p><p><strong>Ethics: </strong>This study has been approved by the National Cancer Center Hospital Certified Review Board in March 2022 and has been approved by the Research Ethics Board of the participating center.</p><p><strong>Discussion: </strong>Our findings will contribute to determining whether MRD detection using TOP is useful for predicting the recurrence of HER2-positive early breast cancer. If this is proven, MRD detected by TOP could be used in the future as a biomarker to assist in the de-/escalation of treatment strategies in the next interventional trial, thereby avoiding overtreatment in patients at low risk, and in the addition of intensive treatment modalities for those in patients at high risk.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases. ENO1作为乳腺癌进展和转移的生物标记物:利用现有数据库的生物信息学方法。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-19 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241285648
Athina Giannoudis, Alistair Heath, Vijay Sharma

Background: Metabolic reprogramming is one of the hallmarks of cancer, and in breast cancer (BC), several metabolic enzymes are overexpressed and overactivated. One of these, Enolase 1 (ENO1), catalyses glycolysis and is involved in the regulation of multiple signalling pathways.

Objectives: This study aimed to evaluate in silico the prognostic and predictive effects of ENO1 expression in BC.

Design: This is a bioinformatic in silico analysis.

Methods: Using available online platforms (Kaplan-Meier [KM] plotter, receiver operating characteristic curve [ROC] plotter, cBioPortal, Genotype-2-Outcome [G-2-O], MethSurv, and Tumour-Immune System Interaction Database [TISIDB]), we performed a bioinformatic in silico analysis to establish the prognostic and predictive effects related to ENO1 expression in BC. A network analysis was performed using the Oncomine platform, and signalling, epigenetic, and immune regulation pathways were explored.

Results: ENO1 was overexpressed in all the analysed Oncomine, epigenetic, and immune pathways in triple-negative, but not in hormone receptor-positive BCs. In human epidermal growth factor receptor 2 (HER2)-positive BCs, ENO1 expression showed a mixed profile. Analysis on disease progression and histological types showed ENO1 overexpression in ductal in situ and invasive carcinoma, in high-grade tumours followed by advanced or metastasis and was linked to worse survival. High ENO1 expression was also associated with relapse-free, distant metastasis-free and overall survival, irrespectively of treatment and was mainly related to basal subtype.

Conclusion: ENO1 overexpression recruits a range of signalling pathways during disease progression conferring a worse prognosis and can be potentially used as a biomarker of disease progression and therapeutic target, particularly in triple-negative and in ductal invasive carcinoma.

背景:代谢重编程是癌症的标志之一,在乳腺癌(BC)中,有几种代谢酶过度表达和过度激活。其中的烯醇化酶1(ENO1)催化糖酵解,并参与多种信号通路的调控:本研究旨在对 BC 中 ENO1 表达的预后和预测作用进行硅学评估:设计:这是一项生物信息学硅学分析:利用现有的在线平台(Kaplan-Meier [KM] plotter、接收者操作特征曲线[ROC] plotter、cBioPortal、Genotype-2-Outcome [G-2-O]、MethSurv和肿瘤-免疫系统相互作用数据库[TISIDB]),我们进行了生物信息学硅学分析,以确定与ENO1在BC中的表达有关的预后和预测作用。我们使用 Oncomine 平台进行了网络分析,探索了信号、表观遗传和免疫调节通路:结果:在所有分析的Oncomine、表观遗传和免疫通路中,ENO1在三阴性而非激素受体阳性的BC中都存在过表达。在人表皮生长因子受体2(HER2)阳性的碱性细胞癌中,ENO1的表达呈现混合型。对疾病进展和组织学类型的分析表明,ENO1在导管原位癌和浸润癌、高级别肿瘤以及晚期或转移癌中过度表达,并与生存率降低有关。ENO1的高表达还与无复发、无远处转移和总生存有关,与治疗无关,主要与基底亚型有关:结论:ENO1的过度表达在疾病进展过程中招募了一系列信号通路,导致预后恶化,有可能被用作疾病进展的生物标记物和治疗靶点,尤其是在三阴性和导管浸润癌中。
{"title":"ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases.","authors":"Athina Giannoudis, Alistair Heath, Vijay Sharma","doi":"10.1177/11782234241285648","DOIUrl":"10.1177/11782234241285648","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming is one of the hallmarks of cancer, and in breast cancer (BC), several metabolic enzymes are overexpressed and overactivated. One of these, Enolase 1 (ENO1), catalyses glycolysis and is involved in the regulation of multiple signalling pathways.</p><p><strong>Objectives: </strong>This study aimed to evaluate in silico the prognostic and predictive effects of ENO1 expression in BC.</p><p><strong>Design: </strong>This is a bioinformatic in silico analysis.</p><p><strong>Methods: </strong>Using available online platforms (Kaplan-Meier [KM] plotter, receiver operating characteristic curve [ROC] plotter, cBioPortal, Genotype-2-Outcome [G-2-O], MethSurv, and Tumour-Immune System Interaction Database [TISIDB]), we performed a bioinformatic in silico analysis to establish the prognostic and predictive effects related to ENO1 expression in BC. A network analysis was performed using the Oncomine platform, and signalling, epigenetic, and immune regulation pathways were explored.</p><p><strong>Results: </strong>ENO1 was overexpressed in all the analysed Oncomine, epigenetic, and immune pathways in triple-negative, but not in hormone receptor-positive BCs. In human epidermal growth factor receptor 2 (HER2)-positive BCs, ENO1 expression showed a mixed profile. Analysis on disease progression and histological types showed ENO1 overexpression in ductal in situ and invasive carcinoma, in high-grade tumours followed by advanced or metastasis and was linked to worse survival. High ENO1 expression was also associated with relapse-free, distant metastasis-free and overall survival, irrespectively of treatment and was mainly related to basal subtype.</p><p><strong>Conclusion: </strong>ENO1 overexpression recruits a range of signalling pathways during disease progression conferring a worse prognosis and can be potentially used as a biomarker of disease progression and therapeutic target, particularly in triple-negative and in ductal invasive carcinoma.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life in Female Breast Cancer Patients and Survivors in a South African Municipality. 南非某市女性乳腺癌患者和幸存者的生活质量。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241282519
Rebecca Wilkinson, Lynn Smith

Background: Breast cancer diagnosis and treatment processes affect patients physically and mentally, and have an impact on their quality of life, even years after receiving treatment.

Objectives: The objective of this study was to determine the quality of life in female breast cancer patients and survivors in a South African context. The municipality within which participants were recruited for this study was Ekurhuleni, based in the Gauteng province, South Africa.

Design: This study followed a cross-sectional research design. Quantitative data was collected.

Methods: The Quality-of-Life Patient/Cancer Survivor Version (2012) was used to determine participants' quality of life in 4 subscales, namely, physical, psychological, social, and spiritual. The questionnaire was accessible to participants via the online Google Forms platform as well as in hard-copy format at local medical facilities. The Statistical Package for Social Sciences (SPSS) was used to compute statistics, and the level of significance was set at 95% (P < .05).

Results: One hundred female breast cancer patients and survivors from the region of Ekurhuleni, South Africa, took part in this study. The findings demonstrate that the quality-of-life subscale with the highest score was spiritual well-being (6.66 ± 2.07) and the lowest was psychological well-being (4.91 ± 1.93). No significant difference was found between quality of life and type of facility attended. Significant differences were found in quality-of-life ratings between breast cancer patient and breast cancer survivor populations.

Conclusion: Breast cancer can result in a compromised quality of life, and with the increased prevalence and survival rate of breast cancer patients, both the short- and long-term effects of the condition and its treatments are heightened.

背景:乳腺癌的诊断和治疗过程会影响患者的身心健康,甚至在接受治疗多年后仍会影响其生活质量:本研究旨在确定南非女性乳腺癌患者和幸存者的生活质量。本研究的参与者被招募到南非豪登省的埃库尔胡莱尼市:本研究采用横断面研究设计,收集定量数据。收集定量数据:采用生活质量患者/癌症幸存者版本(2012 年)来确定参与者在身体、心理、社交和精神四个分量表中的生活质量。参与者可通过在线谷歌表格平台获取问卷,也可在当地医疗机构获取硬拷贝形式的问卷。统计结果采用社会科学统计软件包(SPSS)进行计算,显著性水平设定为 95%(P 结果):来自南非埃库尔胡莱尼地区的 100 名女性乳腺癌患者和幸存者参加了此次研究。研究结果表明,生活质量分量表中得分最高的是精神幸福感(6.66 ± 2.07),最低的是心理幸福感(4.91 ± 1.93)。生活质量与就医机构类型之间没有发现明显差异。乳腺癌患者和乳腺癌幸存者的生活质量评分存在明显差异:结论:乳腺癌可导致生活质量下降,随着乳腺癌发病率和存活率的增加,乳腺癌及其治疗的短期和长期影响也随之增加。
{"title":"Quality of Life in Female Breast Cancer Patients and Survivors in a South African Municipality.","authors":"Rebecca Wilkinson, Lynn Smith","doi":"10.1177/11782234241282519","DOIUrl":"10.1177/11782234241282519","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer diagnosis and treatment processes affect patients physically and mentally, and have an impact on their quality of life, even years after receiving treatment.</p><p><strong>Objectives: </strong>The objective of this study was to determine the quality of life in female breast cancer patients and survivors in a South African context. The municipality within which participants were recruited for this study was Ekurhuleni, based in the Gauteng province, South Africa.</p><p><strong>Design: </strong>This study followed a cross-sectional research design. Quantitative data was collected.</p><p><strong>Methods: </strong>The Quality-of-Life Patient/Cancer Survivor Version (2012) was used to determine participants' quality of life in 4 subscales, namely, physical, psychological, social, and spiritual. The questionnaire was accessible to participants via the online Google Forms platform as well as in hard-copy format at local medical facilities. The Statistical Package for Social Sciences (SPSS) was used to compute statistics, and the level of significance was set at 95% (<i>P</i> < .05).</p><p><strong>Results: </strong>One hundred female breast cancer patients and survivors from the region of Ekurhuleni, South Africa, took part in this study. The findings demonstrate that the quality-of-life subscale with the highest score was spiritual well-being (6.66 ± 2.07) and the lowest was psychological well-being (4.91 ± 1.93). No significant difference was found between quality of life and type of facility attended. Significant differences were found in quality-of-life ratings between breast cancer patient and breast cancer survivor populations.</p><p><strong>Conclusion: </strong>Breast cancer can result in a compromised quality of life, and with the increased prevalence and survival rate of breast cancer patients, both the short- and long-term effects of the condition and its treatments are heightened.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum and Fecal Metabolite Profiles Linking With Gut Microbiome in Triple-Negative Breast Cancer Patients. 三阴性乳腺癌患者血清和粪便代谢物谱与肠道微生物组的关系
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241285645
Jiawei Liu, Jing Shi, Tingting Zhang, Mie Chen, Zhennan Li, Cheng Lu, Fengliang Wang

Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by poor prognosis due to the absence of effective targeted therapies. Emerging evidence indicates that the gut microbiota and its metabolites play a key role in the occurrence and development of TNBC. This study aimed to explore the metabolic changes and potential mechanisms associated with TNBC.

Objectives: This study aimed to explore the potential relationship between targeted metabolites and the gut microbiota in TNBC.

Design: We recruited 8 participants, including 4 with TNBC and 4 with benign fibroadenomas as controls.

Methods: The gut microbiota was analyzed using metagenomics on fecal samples. Liquid chromatography-mass spectrometry (LC-MS) was employed to identify differential metabolites in serum and fecal samples. The correlation between the gut microbiota and metabolites was analyzed using Spearman's correlation analysis.

Results: Analysis of altered serum metabolites in the TNBC group revealed changes, particularly in carboxylic acids and derivatives, benzene, and substituted derivatives. Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway analysis revealed significant enrichment in 18 pathways. Regarding fecal metabolites, differences between the 2 groups also included carboxylic acids and derivatives, benzene, and substituted derivatives, with 28 metabolic pathways enriched based on KEGG pathway analysis. Metagenomics analysis showed differences in the relative abundance of Anaerococcus, Fischerella, and Schizosaccharomyces at the genus level, which have been previously associated with breast cancer. Furthermore, 4 serum metabolites-L-glutamine, citrate, creatinine, and creatine-along with 9 fecal metabolites, were associated with the aforementioned microbiota.

Conclusion: Our findings highlight distinct metabolite profiles in the serum and feces of patients with TNBC. The identification of gut microbiota and their associated metabolites provides new insights into the pathophysiological mechanisms underlying TNBC.

背景:三阴性乳腺癌(TNBC)是乳腺癌的一种亚型,由于缺乏有效的靶向疗法,其预后较差。新的证据表明,肠道微生物群及其代谢产物在 TNBC 的发生和发展中起着关键作用。本研究旨在探讨与 TNBC 相关的代谢变化和潜在机制:本研究旨在探讨 TNBC 靶向代谢物与肠道微生物群之间的潜在关系:我们招募了8名参与者,包括4名TNBC患者和4名良性纤维腺瘤对照组:方法:使用元基因组学分析粪便样本中的肠道微生物群。采用液相色谱-质谱法(LC-MS)鉴定血清和粪便样本中的不同代谢物。利用斯皮尔曼相关分析法分析了肠道微生物群与代谢物之间的相关性:结果:对 TNBC 组血清代谢物变化的分析表明,羧酸及其衍生物、苯和取代衍生物的变化尤为明显。京都基因与基因组百科全书(KEGG)代谢途径分析显示,有18条途径发生了显著富集。在粪便代谢物方面,两组之间的差异还包括羧酸及其衍生物、苯和取代衍生物,根据 KEGG 通路分析,28 条代谢通路被富集。元基因组学分析表明,Anaerococcus、Fischerella 和 Schizosaccharomyces 的相对丰度在属种水平上存在差异,而这些属种以前曾与乳腺癌有关。此外,4种血清代谢物-谷氨酰胺、柠檬酸盐、肌酐和肌酸,以及9种粪便代谢物与上述微生物群相关:我们的研究结果突显了 TNBC 患者血清和粪便中不同的代谢物特征。肠道微生物群及其相关代谢物的鉴定为了解 TNBC 的病理生理机制提供了新的视角。
{"title":"Serum and Fecal Metabolite Profiles Linking With Gut Microbiome in Triple-Negative Breast Cancer Patients.","authors":"Jiawei Liu, Jing Shi, Tingting Zhang, Mie Chen, Zhennan Li, Cheng Lu, Fengliang Wang","doi":"10.1177/11782234241285645","DOIUrl":"10.1177/11782234241285645","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by poor prognosis due to the absence of effective targeted therapies. Emerging evidence indicates that the gut microbiota and its metabolites play a key role in the occurrence and development of TNBC. This study aimed to explore the metabolic changes and potential mechanisms associated with TNBC.</p><p><strong>Objectives: </strong>This study aimed to explore the potential relationship between targeted metabolites and the gut microbiota in TNBC.</p><p><strong>Design: </strong>We recruited 8 participants, including 4 with TNBC and 4 with benign fibroadenomas as controls.</p><p><strong>Methods: </strong>The gut microbiota was analyzed using metagenomics on fecal samples. Liquid chromatography-mass spectrometry (LC-MS) was employed to identify differential metabolites in serum and fecal samples. The correlation between the gut microbiota and metabolites was analyzed using Spearman's correlation analysis.</p><p><strong>Results: </strong>Analysis of altered serum metabolites in the TNBC group revealed changes, particularly in carboxylic acids and derivatives, benzene, and substituted derivatives. Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway analysis revealed significant enrichment in 18 pathways. Regarding fecal metabolites, differences between the 2 groups also included carboxylic acids and derivatives, benzene, and substituted derivatives, with 28 metabolic pathways enriched based on KEGG pathway analysis. Metagenomics analysis showed differences in the relative abundance of <i>Anaerococcus</i>, <i>Fischerella</i>, and <i>Schizosaccharomyces</i> at the genus level, which have been previously associated with breast cancer. Furthermore, 4 serum metabolites-L-glutamine, citrate, creatinine, and creatine-along with 9 fecal metabolites, were associated with the aforementioned microbiota.</p><p><strong>Conclusion: </strong>Our findings highlight distinct metabolite profiles in the serum and feces of patients with TNBC. The identification of gut microbiota and their associated metabolites provides new insights into the pathophysiological mechanisms underlying TNBC.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher 10-Year Survival with Breast-Conserving Therapy over Mastectomy for Women with Early-Stage (I-II) Breast Cancer: Analysis of the CDC Patterns of Care Data Base. 早期(I-II 期)乳腺癌患者接受保乳疗法比乳房切除术的 10 年生存率更高:疾病预防控制中心护理模式数据库分析》。
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241273666
Pratibha Shrestha, Mei-Chin Hsieh, Tekeda Ferguson, Edward S Peters, Edward Trapido, Qingzhao Yu, Quyen D Chu, Xiao-Cheng Wu

Background: Studies in the United States are scarce that assess the survival differences between breast-conserving surgery plus radiation (Breast-Conserving Therapy; BCT) and mastectomy groups using population-based data while accounting for sociodemographic and clinical factors that affect the survival of women with early-stage breast cancer (ESBC).

Objective: To assess whether BCT provides superior long-term overall survival (OS) and breast cancer-specific survival (BCSS) compared with mastectomy in women with ESBC, while considering key factors that impact survival.

Design: Cohort study.

Methods: We analyzed data on women aged 20 years and older diagnosed with stage I-II breast cancer (BC) in 2004 who received either BCT or mastectomy. The data were collected by 5 state cancer registries through the Centers for Disease Control and Prevention-funded Patterns of Care study. Multivariable Cox proportional hazard models, accounting for sociodemographic and clinical factors, were used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). Sensitivity analysis involved optimal caliper propensity score (PS) matching to address residual confounding.

Results: Of the 3495 women, 41.5% underwent mastectomy. The 10-year OS and BCSS were 82.7% and 91.1% for BCT and 72.3% and 85.7% for mastectomy, respectively. Adjusted models showed that mastectomy recipients had a 22% higher risk of all-cause deaths (ACD) (HR = 1.22, 95% CI = [1.06, 1.41]) and a 26% higher risk of breast cancer-specific deaths (BCD) (HR = 1.26, 95% CI = [1.02, 1.55]) than BCT recipients. Sensitivity analysis demonstrated that mastectomy was associated with a higher risk of ACD (P < .05) but did not exhibit a statistically significant risk for BCD. Women with HR+/HER2+ (luminal B) or invasive ductal carcinoma BC who underwent mastectomy had higher risks of ACD and BCD compared with BCT recipients, while the hazards for ACD in triple-negative BC did not remain significant after adjusting for covariates.

Conclusion: ESBC BCT recipients demonstrate superior OS and BCSS compared with mastectomy recipients.

背景:美国很少有研究利用基于人群的数据评估保乳手术加放射治疗(BCT)与乳房切除术组之间的生存率差异,同时考虑影响早期乳腺癌(ESBC)女性患者生存率的社会人口学和临床因素:评估与乳房切除术相比,BCT是否能为ESBC女性患者提供更优越的长期总生存率(OS)和乳腺癌特异性生存率(BCSS),同时考虑影响生存率的关键因素:设计:队列研究:我们分析了 2004 年确诊为 I-II 期乳腺癌 (BC) 的 20 岁及以上女性接受 BCT 或乳房切除术的数据。这些数据由美国疾病控制和预防中心资助的 "护理模式研究 "通过 5 个州的癌症登记处收集。多变量考克斯比例危险模型考虑了社会人口学和临床因素,用于计算危险比 (HR) 和 95% 置信区间 (CI)。敏感性分析包括最佳卡尺倾向评分(PS)匹配,以解决残余混杂因素:在 3495 名妇女中,41.5% 接受了乳房切除术。BCT的10年OS和BCSS分别为82.7%和91.1%,乳房切除术的10年OS和BCSS分别为72.3%和85.7%。调整后的模型显示,乳房切除术接受者的全因死亡风险(ACD)(HR = 1.22,95% CI = [1.06,1.41])比BCT接受者高22%,乳腺癌特异性死亡风险(BCD)(HR = 1.26,95% CI = [1.02,1.55])比BCT接受者高26%。敏感性分析表明,乳房切除术与较高的 ACD 风险相关(P 结论:ESBC BCT 受者显示出较高的乳腺癌特异性死亡风险:ESBC BCT 受者的 OS 和 BCSS 均优于乳房切除术受者。
{"title":"Higher 10-Year Survival with Breast-Conserving Therapy over Mastectomy for Women with Early-Stage (I-II) Breast Cancer: Analysis of the CDC Patterns of Care Data Base.","authors":"Pratibha Shrestha, Mei-Chin Hsieh, Tekeda Ferguson, Edward S Peters, Edward Trapido, Qingzhao Yu, Quyen D Chu, Xiao-Cheng Wu","doi":"10.1177/11782234241273666","DOIUrl":"https://doi.org/10.1177/11782234241273666","url":null,"abstract":"<p><strong>Background: </strong>Studies in the United States are scarce that assess the survival differences between breast-conserving surgery plus radiation (Breast-Conserving Therapy; BCT) and mastectomy groups using population-based data while accounting for sociodemographic and clinical factors that affect the survival of women with early-stage breast cancer (ESBC).</p><p><strong>Objective: </strong>To assess whether BCT provides superior long-term overall survival (OS) and breast cancer-specific survival (BCSS) compared with mastectomy in women with ESBC, while considering key factors that impact survival.</p><p><strong>Design: </strong>Cohort study.</p><p><strong>Methods: </strong>We analyzed data on women aged 20 years and older diagnosed with stage I-II breast cancer (BC) in 2004 who received either BCT or mastectomy. The data were collected by 5 state cancer registries through the Centers for Disease Control and Prevention-funded Patterns of Care study. Multivariable Cox proportional hazard models, accounting for sociodemographic and clinical factors, were used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). Sensitivity analysis involved optimal caliper propensity score (PS) matching to address residual confounding.</p><p><strong>Results: </strong>Of the 3495 women, 41.5% underwent mastectomy. The 10-year OS and BCSS were 82.7% and 91.1% for BCT and 72.3% and 85.7% for mastectomy, respectively. Adjusted models showed that mastectomy recipients had a 22% higher risk of all-cause deaths (ACD) (HR = 1.22, 95% CI = [1.06, 1.41]) and a 26% higher risk of breast cancer-specific deaths (BCD) (HR = 1.26, 95% CI = [1.02, 1.55]) than BCT recipients. Sensitivity analysis demonstrated that mastectomy was associated with a higher risk of ACD (<i>P</i> < .05) but did not exhibit a statistically significant risk for BCD. Women with HR+/HER2+ (luminal B) or invasive ductal carcinoma BC who underwent mastectomy had higher risks of ACD and BCD compared with BCT recipients, while the hazards for ACD in triple-negative BC did not remain significant after adjusting for covariates.</p><p><strong>Conclusion: </strong>ESBC BCT recipients demonstrate superior OS and BCSS compared with mastectomy recipients.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142341717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Opportunities in Breast Cancer by Targeting Macrophage Migration Inhibitory Factor as a Pleiotropic Cytokine. 将巨噬细胞迁移抑制因子作为一种多效细胞因子的乳腺癌治疗机会
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-09-06 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241276310
Ali Khezrian, Ali Shojaeian, Armin Khaghani Boroujeni, Razieh Amini

As a heterogeneous disease, breast cancer (BC) has been characterized by the uncontrolled proliferation of mammary epithelial cells. The tumor microenvironment (TME) also contains inflammatory cells, fibroblasts, the extracellular matrix (ECM), and soluble factors that all promote BC progression. In this sense, the macrophage migration inhibitory factor (MIF), a pleiotropic pro-inflammatory cytokine and an upstream regulator of the immune response, enhances breast tumorigenesis through escalating cancer cell proliferation, survival, angiogenesis, invasion, metastasis, and stemness, which then brings tumorigenic effects by activating key oncogenic signaling pathways and inducing immunosuppression. Against this background, this review was to summarize the current understanding of the MIF pathogenic mechanisms in cancer, particularly BC, and address the central role of this immunoregulatory cytokine in signaling pathways and breast tumorigenesis. Furthermore, different inhibitors, such as small molecules as well as antibodies (Abs) or small interfering RNA (siRNA) and their anti-tumor effects in BC studies were examined. Small molecules and other therapy target MIF. Considering MIF as a promising therapeutic target, further clinical evaluation of MIF-targeted agents in patients with BC was warranted.

作为一种异质性疾病,乳腺癌(BC)的特点是乳腺上皮细胞不受控制的增殖。肿瘤微环境(TME)还包括炎症细胞、成纤维细胞、细胞外基质(ECM)和可溶性因子,它们都会促进乳腺癌的进展。从这个意义上说,巨噬细胞迁移抑制因子(MIF)是一种多向性促炎细胞因子,也是免疫反应的上游调节因子,它通过促进癌细胞增殖、存活、血管生成、侵袭、转移和干性,进而激活关键的致癌信号通路并诱导免疫抑制,从而增强乳腺肿瘤的发生。在此背景下,本综述旨在总结目前对 MIF 在癌症(尤其是 BC)中致病机制的认识,并探讨这种免疫调节细胞因子在信号通路和乳腺肿瘤发生中的核心作用。此外,还研究了不同的抑制剂,如小分子、抗体(Abs)或小干扰 RNA(siRNA)及其在 BC 研究中的抗肿瘤效果。以 MIF 为靶点的小分子和其他疗法。考虑到MIF是一个很有前景的治疗靶点,有必要对MIF靶向药物在BC患者中的应用进行进一步的临床评估。
{"title":"Therapeutic Opportunities in Breast Cancer by Targeting Macrophage Migration Inhibitory Factor as a Pleiotropic Cytokine.","authors":"Ali Khezrian, Ali Shojaeian, Armin Khaghani Boroujeni, Razieh Amini","doi":"10.1177/11782234241276310","DOIUrl":"10.1177/11782234241276310","url":null,"abstract":"<p><p>As a heterogeneous disease, breast cancer (BC) has been characterized by the uncontrolled proliferation of mammary epithelial cells. The tumor microenvironment (TME) also contains inflammatory cells, fibroblasts, the extracellular matrix (ECM), and soluble factors that all promote BC progression. In this sense, the macrophage migration inhibitory factor (MIF), a pleiotropic pro-inflammatory cytokine and an upstream regulator of the immune response, enhances breast tumorigenesis through escalating cancer cell proliferation, survival, angiogenesis, invasion, metastasis, and stemness, which then brings tumorigenic effects by activating key oncogenic signaling pathways and inducing immunosuppression. Against this background, this review was to summarize the current understanding of the MIF pathogenic mechanisms in cancer, particularly BC, and address the central role of this immunoregulatory cytokine in signaling pathways and breast tumorigenesis. Furthermore, different inhibitors, such as small molecules as well as antibodies (Abs) or small interfering RNA (siRNA) and their anti-tumor effects in BC studies were examined. Small molecules and other therapy target MIF. Considering MIF as a promising therapeutic target, further clinical evaluation of MIF-targeted agents in patients with BC was warranted.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Cancer Awareness and Uptake of Breast Cancer Screening Services Among Undergraduate Female Students in the Oldest University of Tanzania: A Cross-Sectional Study. 坦桑尼亚最古老大学女生的乳腺癌意识和接受乳腺癌筛查服务的情况:一项横断面研究
IF 1.8 Q3 ONCOLOGY Pub Date : 2024-08-24 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241274683
Mary Mally, Novatus Tesha, Amani Anaeli

Background: Breast cancer is the leading cause of cancer-related death among women worldwide. Mortality from breast cancer can be reduced through early detection and prevention. Despite the availability of breast cancer screening methods, the uptake of screening services remains very low, especially in low-resource countries like Tanzania. This low uptake of screening services may be attributed to a lack of awareness regarding the importance of early detection of the disease.

Objectives: This study was set to determine breast cancer awareness and the uptake of breast cancer screening services among undergraduate female students in Dar es Salaam, Tanzania.

Design: The study was a descriptive cross-sectional study using the quantitative approach.

Methods: The sample size calculated for this study was 434 undergraduate female students. The tool used for data collection was self-administered questionnaires, with data collection taking place in July 2022. Data were analyzed using Stata Version 15 and presented using descriptive and inferential statistics.

Results: We found that most of the participants (92.38%) had heard about breast cancer, and only 39% of the participants were able to correctly identify the risk factors for breast cancer. Participants who had ever used breast cancer screening services by at least 1 method were 37 (9.23%), and the most common screening method practiced by the study participants was breast self-examination (48.65%).

Conclusions: Most of the participants were not aware of the screening methods for early detection of breast cancer. In addition, they lacked knowledge of some of the risk factors as evidenced by the low uptake of breast cancer screening services among the study participants. This calls for an awareness-raising campaign on the importance of breast cancer screening.

背景:乳腺癌是全球妇女因癌症死亡的主要原因。乳腺癌的死亡率可以通过早期检测和预防来降低。尽管有乳腺癌筛查方法,但筛查服务的接受率仍然很低,尤其是在坦桑尼亚这样的低资源国家。筛查服务接受率低的原因可能是人们对早期发现乳腺癌的重要性缺乏认识:本研究旨在了解坦桑尼亚达累斯萨拉姆大学女生对乳腺癌的认识以及接受乳腺癌筛查服务的情况:设计:本研究是一项描述性横断面研究,采用定量方法:本研究的样本量为 434 名本科女学生。数据收集工具为自填式问卷,数据收集时间为 2022 年 7 月。数据使用 Stata 15 版进行分析,并使用描述性和推论性统计进行展示:我们发现,大多数参与者(92.38%)听说过乳腺癌,只有 39% 的参与者能够正确识别乳腺癌的风险因素。曾经至少使用过一种方法进行乳腺癌筛查的参与者有 37 人(9.23%),最常见的筛查方法是乳房自我检查(48.65%):结论:大多数参与者不了解早期发现乳腺癌的筛查方法。此外,他们对一些风险因素也缺乏了解,这一点从研究参与者对乳腺癌筛查服务的接受程度较低可以看出。这就需要开展宣传活动,提高人们对乳腺癌筛查重要性的认识。
{"title":"Breast Cancer Awareness and Uptake of Breast Cancer Screening Services Among Undergraduate Female Students in the Oldest University of Tanzania: A Cross-Sectional Study.","authors":"Mary Mally, Novatus Tesha, Amani Anaeli","doi":"10.1177/11782234241274683","DOIUrl":"10.1177/11782234241274683","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the leading cause of cancer-related death among women worldwide. Mortality from breast cancer can be reduced through early detection and prevention. Despite the availability of breast cancer screening methods, the uptake of screening services remains very low, especially in low-resource countries like Tanzania. This low uptake of screening services may be attributed to a lack of awareness regarding the importance of early detection of the disease.</p><p><strong>Objectives: </strong>This study was set to determine breast cancer awareness and the uptake of breast cancer screening services among undergraduate female students in Dar es Salaam, Tanzania.</p><p><strong>Design: </strong>The study was a descriptive cross-sectional study using the quantitative approach.</p><p><strong>Methods: </strong>The sample size calculated for this study was 434 undergraduate female students. The tool used for data collection was self-administered questionnaires, with data collection taking place in July 2022. Data were analyzed using Stata Version 15 and presented using descriptive and inferential statistics.</p><p><strong>Results: </strong>We found that most of the participants (92.38%) had heard about breast cancer, and only 39% of the participants were able to correctly identify the risk factors for breast cancer. Participants who had ever used breast cancer screening services by at least 1 method were 37 (9.23%), and the most common screening method practiced by the study participants was breast self-examination (48.65%).</p><p><strong>Conclusions: </strong>Most of the participants were not aware of the screening methods for early detection of breast cancer. In addition, they lacked knowledge of some of the risk factors as evidenced by the low uptake of breast cancer screening services among the study participants. This calls for an awareness-raising campaign on the importance of breast cancer screening.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fertility and Pregnancy-Related Issues in Young BRCA Carriers With Breast Cancer. 患有乳腺癌的年轻 BRCA 携带者的生育和妊娠相关问题。
IF 2.9 Q3 Medicine Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241261429
Isotta Martha Magaton, Luca Arecco, Elene Mariamidze, Kristina Jankovic, Mihaela Stana, Giulia Buzzatti, Lucia Trevisan, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Claudia Massarotti, Michael von Wolff, Matteo Lambertini

Approximately 10% to 15% of breast cancer cases in young women are diagnosed in patients harbouring germline (g) pathogenic or likely pathogenic variants (PVs) in the BReast CAncer 1 (BRCA1) or BReast CAncer 2 (BRCA2) genes. Preclinical and clinical studies showed a potential negative effect of germline BRCA1/2 (gBRCA1/2) PVs on ovarian reserve and reproductive potential, even before starting anticancer therapies. The aim of this article is to summarize the current literature on the fertility potential of young gBRCA1/2 PVs carriers with breast cancer and the risk of gonadotoxicity associated with anticancer treatments. Moreover, we describe the available evidence on the efficacy of fertility preservation techniques in young gBRCA1/2 PVs carriers and the safety data on having a pregnancy after breast cancer treatment.

在年轻女性的乳腺癌病例中,约有 10%-15%的患者被诊断出携带乳腺癌基因 1(BRCA1)或乳腺癌基因 2(BRCA2)的种系(g)致病变体或可能致病变体(PVs)。临床前和临床研究表明,即使在开始接受抗癌治疗之前,种系 BRCA1/2 (gBRCA1/2) PVs 对卵巢储备和生殖潜能也有潜在的负面影响。本文旨在总结目前有关年轻乳腺癌 gBRCA1/2 PVs 携带者生育潜能以及抗癌治疗相关性腺毒性风险的文献。此外,我们还介绍了有关年轻的 gBRCA1/2 PVs 携带者生育力保存技术疗效的现有证据,以及乳腺癌治疗后怀孕的安全性数据。
{"title":"Fertility and Pregnancy-Related Issues in Young <i>BRCA</i> Carriers With Breast Cancer.","authors":"Isotta Martha Magaton, Luca Arecco, Elene Mariamidze, Kristina Jankovic, Mihaela Stana, Giulia Buzzatti, Lucia Trevisan, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Claudia Massarotti, Michael von Wolff, Matteo Lambertini","doi":"10.1177/11782234241261429","DOIUrl":"10.1177/11782234241261429","url":null,"abstract":"<p><p>Approximately 10% to 15% of breast cancer cases in young women are diagnosed in patients harbouring germline (g) pathogenic or likely pathogenic variants (PVs) in the BReast CAncer 1 (<i>BRCA1</i>) or BReast CAncer 2 (<i>BRCA2</i>) genes. Preclinical and clinical studies showed a potential negative effect of germline <i>BRCA</i>1/2 (g<i>BRCA1/2</i>) PVs on ovarian reserve and reproductive potential, even before starting anticancer therapies. The aim of this article is to summarize the current literature on the fertility potential of young g<i>BRCA1/2</i> PVs carriers with breast cancer and the risk of gonadotoxicity associated with anticancer treatments. Moreover, we describe the available evidence on the efficacy of fertility preservation techniques in young g<i>BRCA1/2</i> PVs carriers and the safety data on having a pregnancy after breast cancer treatment.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes-A Meta-analysis. 腋窝淋巴结阴性的乳腺癌患者在新辅助化疗后进行前哨淋巴结活检的可行性和可靠性--一项 Meta 分析。
IF 2.9 Q3 Medicine Pub Date : 2024-05-30 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241255856
Mengjie Yu, Yu Liu, Zenan Huang, Qingqing Zhu, Yong Huang

Background: The application of sentinel lymph node biopsy (SLNB) has expanded from early breast cancer to locally advanced breast cancer with neoadjuvant chemotherapy (NAC). For patients with negative axillary lymph nodes, performing SLNB before or after NAC remains controversial.

Objectives: To evaluate the diagnostic feasibility and reliability of SLNB after NAC in breast cancer patients with negative axillary nodes at initial diagnosis.

Design: To calculate pooled identification rate (IR) and false negative rate (FNR) of SLNB after NAC on breast cancer patients with initially negative axillary nodes by enrolling relevant studies and perform subgroup analysis by the type of tracer and the number of biopsied sentinel lymph nodes in average.

Data sources and methods: The PubMed, Embase, Cochrane, Web of Science, and Scopus databases from January 1, 2002, to March 1, 2022, were searched for studies. The QUADAS-2 tool and MINORS item were employed to evaluate the quality of the included studies. I2 and Q tests were used to evaluate the heterogeneity among the studies. Random-effects model and fixed-effects model were employed to calculate the pooled IR, FNR, and 95% confidence interval (CI). Publication bias was evaluated, and sensitivity analysis was performed. Subgroup analysis was performed according to the type of tracer (single/double) and the number of biopsied sentinel lymph nodes in average (⩽2/>2).

Results: A total of 21 studies covering 1716 patients were enrolled in this study (IR = 93%, 95% CI = 90-96; FNR = 8%, 95% CI = 6-11).

Conclusion: The SLNB after NAC can serve as a feasible and reliable approach in breast cancer patients with negative axillary lymph node. In our study, no significant impact of tracer was found on the IR and FNR of SLNB, and the number of biopsy nodes >2 leads to the decreased FNR of SLNB.

背景:前哨淋巴结活检(SLNB)的应用已从早期乳腺癌扩展到接受新辅助化疗(NAC)的局部晚期乳腺癌。对于腋窝淋巴结阴性的患者,在新辅助化疗之前还是之后进行前哨淋巴结活检仍存在争议:评估对初诊时腋窝淋巴结阴性的乳腺癌患者在 NAC 后进行 SLNB 诊断的可行性和可靠性:设计:通过纳入相关研究,计算NAC后SLNB对初始腋窝结节阴性的乳腺癌患者的集合识别率(IR)和假阴性率(FNR),并根据示踪剂类型和活检前哨淋巴结的平均数量进行亚组分析:对2002年1月1日至2022年3月1日期间的PubMed、Embase、Cochrane、Web of Science和Scopus数据库进行了研究检索。采用QUADAS-2工具和MINORS项目来评估纳入研究的质量。采用 I2 和 Q 检验来评估研究之间的异质性。采用随机效应模型和固定效应模型计算汇总的IR、FNR和95%置信区间(CI)。评估了发表偏倚,并进行了敏感性分析。根据示踪剂的类型(单/双)和活检前哨淋巴结的平均数量(⩽2/>2)进行亚组分析:本研究共纳入21项研究,覆盖1716名患者(IR = 93%,95% CI = 90-96;FNR = 8%,95% CI = 6-11):结论:对于腋窝淋巴结阴性的乳腺癌患者,在 NAC 后进行 SLNB 是一种可行且可靠的方法。我们的研究发现,示踪剂对SLNB的IR和FNR无明显影响,活检结节数大于2会导致SLNB的FNR下降。
{"title":"The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes-A Meta-analysis.","authors":"Mengjie Yu, Yu Liu, Zenan Huang, Qingqing Zhu, Yong Huang","doi":"10.1177/11782234241255856","DOIUrl":"10.1177/11782234241255856","url":null,"abstract":"<p><strong>Background: </strong>The application of sentinel lymph node biopsy (SLNB) has expanded from early breast cancer to locally advanced breast cancer with neoadjuvant chemotherapy (NAC). For patients with negative axillary lymph nodes, performing SLNB before or after NAC remains controversial.</p><p><strong>Objectives: </strong>To evaluate the diagnostic feasibility and reliability of SLNB after NAC in breast cancer patients with negative axillary nodes at initial diagnosis.</p><p><strong>Design: </strong>To calculate pooled identification rate (IR) and false negative rate (FNR) of SLNB after NAC on breast cancer patients with initially negative axillary nodes by enrolling relevant studies and perform subgroup analysis by the type of tracer and the number of biopsied sentinel lymph nodes in average.</p><p><strong>Data sources and methods: </strong>The PubMed, Embase, Cochrane, Web of Science, and Scopus databases from January 1, 2002, to March 1, 2022, were searched for studies. The QUADAS-2 tool and MINORS item were employed to evaluate the quality of the included studies. <i>I</i><sup>2</sup> and Q tests were used to evaluate the heterogeneity among the studies. Random-effects model and fixed-effects model were employed to calculate the pooled IR, FNR, and 95% confidence interval (CI). Publication bias was evaluated, and sensitivity analysis was performed. Subgroup analysis was performed according to the type of tracer (single/double) and the number of biopsied sentinel lymph nodes in average (⩽2/>2).</p><p><strong>Results: </strong>A total of 21 studies covering 1716 patients were enrolled in this study (IR = 93%, 95% CI = 90-96; FNR = 8%, 95% CI = 6-11).</p><p><strong>Conclusion: </strong>The SLNB after NAC can serve as a feasible and reliable approach in breast cancer patients with negative axillary lymph node. In our study, no significant impact of tracer was found on the IR and FNR of SLNB, and the number of biopsy nodes >2 leads to the decreased FNR of SLNB.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature. 激素受体阳性、HER2 阴性早期乳腺癌中 Ki-67 增殖指数与 Oncotype-Dx 复发评分之间的关系。文献的系统回顾。
IF 2.9 Q3 Medicine Pub Date : 2024-05-20 eCollection Date: 2024-01-01 DOI: 10.1177/11782234241255211
Mehwish Mooghal, Muhammad Ali Akbar Khan, Mirza Rameez Samar, Hafsa Shaikh, Azmina Tajdin Valimohammad, Romana Idrees, Yasmin Abdul Rashid, Abida K Sattar

Background: Oncotype-Dx (ODx) is a 21-gene assay used as a prognostic and predictive tool for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, node-negative, or 1 to 3 lymph node-positive early breast cancers (EBCs). The cost of the test, which is not available in low-middle income countries (LMICs), is not within the means of most individuals. The Ki-67 index is a marker of tumor proliferation that is cost-effective and easily performed and has been substituted in many cases to obtain prognostic information.

Objective: We aimed to identify the correlation between the ODx recurrence score (RS) and the Ki-67 index in HR-positive EBCs and to determine whether Ki-67, like the ODx, can help facilitate clinical decision-making.

Design: Systematic review correlating Ki-67 index and ODx in HR-positive and HER2-negative EBCs as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Data sources and methods: We searched different databases between January 2010 and May 2023 and included retrospective/prospective cohorts, clinical trials, case-control, and cross-sectional studies involving HR-positive and HER2-negative EBCs correlating the Ki-67 index and ODx RS categories.

Results: Of the 18 studies included, 16 indicated a positive or weakly positive correlation between ODx and the Ki-67 index. The combined P value of the included studies is <0.05 (P = .000), which shows a statistical significance between the 2. Our review also discusses the potential of machine learning and artificial intelligence (AI) in Ki-67 assessment, offering a cost-effective and reproducible alternative.

Conclusion: Even although there are limitations, studies indicate a favorable association between ODx and the Ki-67 index in specific situations. This implies that Ki-67 can offer important predictive details, especially regarding the likelihood of relapse in HR-positive EBC. This is particularly significant in LMICs where financial constraints often hinder the availability of costly diagnostic tests.

背景:Oncotype-Dx(ODx)是一种 21 基因检测法,用于激素受体(HR)阳性和人类表皮生长因子受体 2(HER2)阴性、结节阴性或 1 至 3 个淋巴结阳性的早期乳腺癌(EBC)的预后和预测。中低收入国家(LMIC)无法提供这种检测,其费用也不是大多数人所能承受的。Ki-67指数是一种肿瘤增殖标志物,成本低、操作简便,在许多病例中被用来替代Ki-67指数,以获得预后信息:我们旨在确定 HR 阳性 EBC 的 ODx 复发评分 (RS) 与 Ki-67 指数之间的相关性,并确定 Ki-67 是否与 ODx 一样有助于促进临床决策:设计:根据《系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-Analyses,PRISMA)指南,对HR阳性和HER2阴性EBC的Ki-67指数和ODx进行相关性系统综述:我们检索了 2010 年 1 月至 2023 年 5 月期间的不同数据库,纳入了涉及 HR 阳性和 HER2 阴性 EBC、与 Ki-67 指数和 ODx RS 分类相关的回顾性/前瞻性队列、临床试验、病例对照和横断面研究:在纳入的 18 项研究中,16 项研究表明 ODx 与 Ki-67 指数呈正相关或弱正相关。我们的综述还讨论了机器学习和人工智能(AI)在 Ki-67 评估中的潜力,它提供了一种具有成本效益和可重复性的替代方法:结论:尽管存在局限性,但研究表明,在特定情况下,ODx 与 Ki-67 指数之间存在有利的关联。这意味着 Ki-67 可以提供重要的预测细节,尤其是关于 HR 阳性 EBC 复发的可能性。这对于经济拮据的低收入国家尤为重要,因为这些国家往往无法获得昂贵的诊断测试。
{"title":"Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.","authors":"Mehwish Mooghal, Muhammad Ali Akbar Khan, Mirza Rameez Samar, Hafsa Shaikh, Azmina Tajdin Valimohammad, Romana Idrees, Yasmin Abdul Rashid, Abida K Sattar","doi":"10.1177/11782234241255211","DOIUrl":"10.1177/11782234241255211","url":null,"abstract":"<p><strong>Background: </strong>Oncotype-Dx (ODx) is a 21-gene assay used as a prognostic and predictive tool for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, node-negative, or 1 to 3 lymph node-positive early breast cancers (EBCs). The cost of the test, which is not available in low-middle income countries (LMICs), is not within the means of most individuals. The Ki-67 index is a marker of tumor proliferation that is cost-effective and easily performed and has been substituted in many cases to obtain prognostic information.</p><p><strong>Objective: </strong>We aimed to identify the correlation between the ODx recurrence score (RS) and the Ki-67 index in HR-positive EBCs and to determine whether Ki-67, like the ODx, can help facilitate clinical decision-making.</p><p><strong>Design: </strong>Systematic review correlating Ki-67 index and ODx in HR-positive and HER2-negative EBCs as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.</p><p><strong>Data sources and methods: </strong>We searched different databases between January 2010 and May 2023 and included retrospective/prospective cohorts, clinical trials, case-control, and cross-sectional studies involving HR-positive and HER2-negative EBCs correlating the Ki-67 index and ODx RS categories.</p><p><strong>Results: </strong>Of the 18 studies included, 16 indicated a positive or weakly positive correlation between ODx and the Ki-67 index. The combined <i>P</i> value of the included studies is <0.05 (<i>P</i> = .000), which shows a statistical significance between the 2. Our review also discusses the potential of machine learning and artificial intelligence (AI) in Ki-67 assessment, offering a cost-effective and reproducible alternative.</p><p><strong>Conclusion: </strong>Even although there are limitations, studies indicate a favorable association between ODx and the Ki-67 index in specific situations. This implies that Ki-67 can offer important predictive details, especially regarding the likelihood of relapse in HR-positive EBC. This is particularly significant in LMICs where financial constraints often hinder the availability of costly diagnostic tests.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast Cancer : Basic and Clinical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1